RT Journal Article
SR Electronic
T1 Correction<em>: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer</em>
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP 1
OP 1
DO 10.1136/jitc-2020-001622corr1
VO 9
IS 2
YR 2021
UL http://jitc.bmj.com/content/9/2/1.abstract